Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Immutep LimitedNASDAQ: IMMP

Other Income / Expenses · Q2 FY2026 · quarter ended Dec 2025

Other income / expenses declines year over year

Q2 FY2026 other income / expenses of A$1.17M fell 96.0% year over year. Over 3 fiscal years it compounded at +241.9% a year.

Context

  • Other income / expenses amounted to 1288.5% of revenue in FY2025, up 107.1 pp from a year earlier.
  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$1.17M— QoQ
Last fiscal yearJun 2025
A$64.99M+43.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-96.0%——
1 year+43.2%——
3-year CAGR+241.9%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

AUD · from the income statement

Latest · FY2025
64.99M AUD
Year-over-year change
+43.2%
4-year CAGR
+146.0%

Other Income / Expenses vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.2% is the 5th highest of 11, against a peer median of -17.8%.
  • Other income / expenses amounts to 1288.5% of revenue for IMMP, versus a peer median of 15.9%.
IMMP Competitors
Other Income / Expenses for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMMPImmutep LimitedFY2025A$64.99M AUD+43.2%+241.9%1288.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$16.46M USD-3.2%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$13.26M USD-32.7%+71.0%231.0%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$10.66M USD-47.6%+36.1%4.9%
EDITEditas Medicine, Inc.LTM Mar 2026$6.16M USD-32.3%—15.9%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$5.34M USD+140.8%+66.0%—
CABACabaletta Bio, Inc.LTM Mar 2026$3.97M USD-46.9%+55.6%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$2M USD+133.4%-14.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.86M USD+124.8%—372.3%
PRQRProQR Therapeutics N.V.LTM Mar 2026€840.44K EUR-70.3%+16.3%6.3%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$460K USD+357.0%——
Peer median (excluding IMMP) —-17.8%+45.8%15.9%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue3.86M170.37K3.51M3.84M5.04M
Cost of Revenue17.24M2.06M2.06M41.55M61.41M
Gross Profit(13.37M)(1.89M)1.44M(37.7M)(56.37M)
Gross Margin-346.2%-1111.2%41.2%-981.4%-1117.6%
Research & Development17.24M31.34M28.79M41.55M61.41M
Selling, General & Admin6.28M7.21M14.08M8.85M8.64M
Operating Expenses18.3M32.55M44.94M50.4M70.06M
Depreciation & Amortization1.89M1.84M1.86M2.01M2.13M
EBITDA(17.77M)(31.87M)(39.57M)(44.54M)(62.88M)
EBITDA Margin-460.0%-18708.9%-1128.8%-1159.4%-1246.6%
Operating Income(31.68M)(33.94M)(77.69M)(88.1M)(126.42M)
Operating Margin-820.0%-19920.0%-2216.0%-2293.3%-2506.5%
Interest Income105.33K224.52K939K3.88M5.25M
Interest Expense9.83K92.43K20.4K30.59K24.01K
Other Income / Expenses1.77M1.63M37.79M45.39M64.99M
Income Before Tax(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Pre-Tax Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
Income Tax Expense3334000
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Net Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
EPS (Basic)(0.49)(0.37)(0.44)(0.36)(0.42)
EPS (Diluted)(0.49)(0.37)(0.44)(0.36)(0.42)
Weighted Avg Shares60.43M86.23M90.06M119.99M145.58M
Weighted Avg Shares (Diluted)60.43M86.23M90.06M120.11M145.58M

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.